WATCHLONGEVITY

Saturday, July 4, 2026

DEVELOPING
Importance
62
Trust
73
Urgency
65
COMMERCIAL · PRIMARY SOURCE

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management

Eli Lilly launched a Medicare program on July 1 that helps seniors with Medicare Part D insurance get its weight-loss drugs Foundayo (a daily pill) and Zepbound (an injectable). The new pathway makes these medicines more affordable for older patients.

Analysis

Lilly opened a Medicare access path for Foundayo and Zepbound on July 1. This could lower costs for seniors who couldn't afford these weight-loss drugs before.

  • Eli Lilly launched a Medicare Part D program on July 1 for Foundayo and Zepbound
  • Foundayo (orforglipron) is a daily pill; Zepbound (tirzepatide) is an injectable
  • Program targets weight management access for Medicare Part D patients
$LLY
orforgliprontirzepatideEli Lilly
Eli Lilly Press Releases8d
Read
DEVELOPING
Importance
82
Trust
79
Urgency
65
CLINICAL TRIAL · PRIMARY SOURCE✓ 2 outlets

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

Eli Lilly's pill version of orforglipron (Foundayo) beat Novo Nordisk's semaglutide pill at lowering blood sugar and weight loss in three large diabetes trials. Foundayo showed bigger drops in A1C levels and weight compared to the competing drug.

Analysis

Lilly's orforglipron pill beat Novo's semaglutide pill on blood sugar and weight in three trials. That puts Lilly in a strong spot in the oral diabetes drug race.

  • Orforglipron (Foundayo) showed superior A1C control vs semaglutide pill in three pivotal type 2 diabetes trials
  • Foundayo also showed greater weight loss than the competing semaglutide pill
  • Data came from three separate pivotal trials per Eli Lilly press release
$LLY$NVO
orforglipronsemaglutideEli LillyNovo Nordisk
Eli Lilly Press Releases25d
Read
Importance
62
Trust
79
Urgency
30
CLINICAL TRIAL · PRIMARY SOURCE✓ 2 outlets

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

Eli Lilly's Foundayo (orforglipron), an oral weight-loss drug you can take with food or water, helped women lose significant weight in two trials. Women in perimenopause lost up to 30.4 pounds, and those past menopause lost up to 28.2 pounds.

Analysis

Orforglipron showed weight loss in women at all menopause stages. This expands the pool of patients Lilly can target with its oral GLP-1 pill.

  • Foundayo (orforglipron) can be taken without food or water restrictions
  • Women in perimenopause lost up to 30.4 pounds in trial data
  • Women past menopause lost up to 28.2 pounds
$LLY
orforglipronEli Lilly
Eli Lilly Press Releases26d
Read
Importance
62
Trust
73
Urgency
30
CLINICAL TRIAL · PRIMARY SOURCE

Foundayo (orforglipron), a once-daily pill taken without food or water restrictions, was associated with reduced body weight of up to 13% in adults 65 and older with obesity or overweight, in new analysis of ATTAIN-1/2

Eli Lilly's new weight-loss pill Foundayo helped older adults lose up to 13% of their body weight in a large trial. The drug is taken once daily without needing to avoid food or water first.

Analysis

Foundayo showed up to 13% weight loss in adults 65+ with obesity. This age group is a large, underserved market for Lilly's oral pill.

  • Foundayo (orforglipron) linked to up to 13% body weight reduction in adults 65 and older
  • Analysis drawn from ATTAIN-1 and ATTAIN-2 trials
  • Drug is taken once daily with no food or water restrictions
$LLY
orforglipronEli Lilly
Eli Lilly Press Releases1mo
Read
Novel Drug Approvals for 2026
BREAKING
Importance
95
Trust
89
Urgency
95
APPROVAL · PRIMARY SOURCE

Novel Drug Approvals for 2026

The FDA approved orforglipron (Foundayo) on April 1, 2026, a new peptide drug to help adults with obesity lose weight and keep it off. The approval also included insulin icodec-abae (Awiqli) for type 2 diabetes and several other peptide-based therapies for rare diseases.

Analysis

Lilly's Foundayo is the first oral GLP-1 pill approved for obesity. Patients can now skip the weekly shot. Novo's weekly insulin Awiqli also got the green light.

  • FDA approved Foundayo (orforglipron) on 4/1/2026 for adults with obesity
  • Foundayo is for use with a reduced-calorie diet and exercise
  • FDA approved Awiqli (insulin icodec-abae) on 3/26/2026 for type 2 diabetes
$LLY$NVO
orforgliproninsulin icodec-abaenavepegritidepegzilarginase-nbln
FDA Drug Approvals & Databases2mo
Read
BREAKING
Importance
78
Trust
71
Urgency
95
COMMERCIAL

Lilly's obesity pill hits nearly 6,000 prescriptions in third week after launch - Reuters

Eli Lilly's obesity pill reached nearly 6,000 prescriptions in its third week on the market. The quick uptake shows strong early demand for the company's weight-loss drug.

Analysis

Lilly's pill is selling fast right out of the gate. A pill is easier than a shot, so it could pull patients away from Novo's weight-loss drugs.

  • Lilly's obesity pill hit nearly 6,000 prescriptions in week three after launch
$LLY
orforglipronEli Lilly
Reuters Health2mo
Read